Uploaded August 2025 | Updated September 2026, 1 week ago
Bradley Gelfand, PhD is an associate professor of ophthalmology.
Transcript
I love the thrill of discovery. I love finding out new information and answers to interesting questions. I feel like a kid on Christmas opening up presents. That's what keeps me going. That's really what keeps me engaged and interested in research. My name is Bradley Gelfand. I'm an associate professor of Ophthalmology. I run a research lab whose primary interest is in understanding the mechanisms and potential new therapies for prevalent diseases of the retina, like age-related macular degeneration. My research, I hope, can impact human health in a couple of different ways. First, we're very interested in the underlying causes of retinal diseases, like age-related macular degeneration. By developing a better understanding of how this disease progresses, we hope to ultimately one day develop new kinds of therapies that can help prevent or delay the loss of vision, particularly as people age. In addition, we have a variety of different new exciting therapies and therapeutic strategies that we're very excited about and hope to one day be able to translate to people who currently have the disease.
Bradley Gelfand, PhD is an associate professor of ophthalmology.
Transcript
I love the thrill of discovery. I love finding out new information and answers to interesting questions. I feel like a kid on Christmas opening up presents. That's what keeps me going. That's really what keeps me engaged and interested in research. My name is Bradley Gelfand. I'm an associate professor of Ophthalmology. I run a research lab whose primary interest is in understanding the mechanisms and potential new therapies for prevalent diseases of the retina, like age-related macular degeneration. My research, I hope, can impact human health in a couple of different ways. First, we're very interested in the underlying causes of retinal diseases, like age-related macular degeneration. By developing a better understanding of how this disease progresses, we hope to ultimately one day develop new kinds of therapies that can help prevent or delay the loss of vision, particularly as people age. In addition, we have a variety of different new exciting therapies and therapeutic strategies that we're very excited about and hope to one day be able to translate to people who currently have the disease.
